Feasibility of Blood Glucose Control With the Space TGC System in Medical ICU Patients (DELIOS 01)

This study has been completed.
Sponsor:
Information provided by:
B. Braun Melsungen AG
ClinicalTrials.gov Identifier:
NCT01164423
First received: July 15, 2010
Last updated: February 8, 2011
Last verified: February 2011

July 15, 2010
February 8, 2011
July 2010
December 2010   (final data collection date for primary outcome measure)
(arterial) blood glucose values -> percentage of time within predefined glucose target range 80-150 mg/dL [ Time Frame: all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 14d ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01164423 on ClinicalTrials.gov Archive Site
  • Hypoglycaemia ≤ 40 mg/dl (2.2mM) [ Time Frame: all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 14d ] [ Designated as safety issue: Yes ]
  • Concomitant medication including insulin infusion rate, parenteral/enteral nutrition [ Time Frame: all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 14d ] [ Designated as safety issue: No ]
  • Usability parameters like convenience of alarming function; workload; blood sampling frequency [ Time Frame: all blood glucose measurements from start of treatment until last glucose measurement under treatment (i.e. stop of intravenous insulin treatment) up to a maximum of 14d ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Feasibility of Blood Glucose Control With the Space TGC System in Medical ICU Patients
Monocentric, Open Study to Investigate the Feasibility of Blood Glucose Control With the Space TGC System (With Incorporated Software-algorithm eMPC) in Medical ICU Patients

Hyperglycemia is common in critically ill patients and associated with an adverse outcome. Thus, glycaemic control is an important issue in critical care. Despite extensive efforts of the intensive care unit staff difficulties were experienced in achieving efficient and safe glucose control. A fully automated algorithm may help to overcome some of these limitations by excluding intuitive interventions and integrating relevant clinical data in the decision-making process. Space GlucoseControl (TGC system) is a decision support system which helps to achieve safe and reliable blood glucose control in the desired ranges. Information on parenteral and enteral nutrition is automatically integrated into the calculations. The primary objective of the current study is to investigate the performance and usability of the Space TGC system for glucose control in medical ICU patients.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Critical Illness
Device: Space TGC
Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
Experimental: 1
Space TGC system with incorporated eMPC advised insulin infusion to establish glycaemic control
Intervention: Device: Space TGC

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion:

  • age: > 18 years of age
  • stay in the ICU expected to be > 72 h
  • blood glucose > 110 mg/dl or patient on insulin treatment

Exclusion:

  • patients with hyperglycaemic crisis/ketoacidosis due to insulin deficiency.
  • known or suspected allergy to insulin
  • any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient (i.e., liver failure, other fatal organ failures)
  • moribund patients likely to die within 24 hours
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
NCT01164423
HC-G-H-0905
No
Dr. Norman Kachel, B. Braun Melsungen AG
B. Braun Melsungen AG
Not Provided
Principal Investigator: Thomas R. Pieber, Prof. Landeskrankenhaus Universitätsklinikum Graz
B. Braun Melsungen AG
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP